Xbrane Biopharma AB (XBRANE)
Stockholm Exchange · Sweden · prices in SEK · close of 23 Oct 2026
Key indicators
| Last close | SEK 12.00 |
|---|---|
| 52-week range | 5.42 – 15.25 |
| Return, 1 month / 3 months | +13.2% / +18.2% |
| Return, 1 year / 3 years | −21.3% / −95.7% |
| Trend | Uptrend |
| RSI (14) | 51 |
| Volatility (1 year) | 82.1% |
| Worst drawdown (1 year) | -62.9% |
| Average daily value traded | 0.45M SEK |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Xbrane Biopharma is a Swedish biopharmaceutical company that develops biosimilar medicines, which are copies of biologic drugs that have lost patent protection. Its work centres on treatments for eye disorders and on protein production technology, including a bacterial expression platform used to manufacture proteins. The company serves pharmaceutical markets through partnerships and licensing arrangements, and it is based in Sweden, where its development and production activities are organised.
The shares are listed on the Stockholm Exchange in Sweden under the code XBRANE, and the price on this page is in Swedish kronor (SEK). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Xbrane Biopharma AB (XBRANE) trades on the Stockholm Exchange in Sweden. It last closed at SEK 12.00 on 23 October 2026.
Its price-based Market X-Ray is 55 out of 100 (a fair price profile), ranking 406 of 912 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 21.3% and over the last three months it rose 18.2%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Stockholm Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 79 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 21.8% | ||
| From 52-week high | -21.3% | ||
| Momentum | 67 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 18.2% | ||
| 6-month return | 27.7% | ||
| 12-month return, skipping the last month | -30.5% | ||
| Stability (higher is calmer) | 23 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 82.1% | ||
| Worst drawdown, 1 year (smaller is calmer) | -62.9% | ||
| Liquidity | 49 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.45M SEK | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +5.3% |
|---|---|
| 1 month | +13.2% |
| 3 months | +18.2% |
| 6 months | +27.7% |
| 1 year | −21.3% |
| 3 years | −95.7% |
| 5 years | −99.3% |
Signals
| 50-day / 200-day average | 10.87 / 9.85 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 1.00 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Stockholm Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.